Retraining the brain to see again: a new hope for Stroke-Related blindness
NCT ID NCT05098236
First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time
Summary
This study tests whether intensive visual retraining at home can help people who have lost part of their vision due to damage to the brain's visual cortex, often from a stroke. Participants will use a computer program to practice detecting motion and orientation of visual stimuli in their blind field, with sessions one to two times daily. The goal is to see if this training can improve visual perception and whether any gains carry over to everyday vision. The study involves 280 participants and measures changes in visual abilities over up to a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A computer-based visual training program used at home, involving repeated tasks to discriminate motion or orientation of visual stimuli in the blind field.
- What this could lead to
- If effective, this training could offer a non-invasive way to partially restore vision in people with visual field loss after brain damage, improving daily functioning.
- What could go wrong
- The training may not work for everyone, and results are uncertain because the study is early and relies on self-reported home practice. There is also a risk of no significant improvement in real-world vision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
280 people
The number who actually took part.
- Started
-
Sep 2003
- Finished
-
Jun 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
17 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Cortically Blind Subject Inclusion Criteria: * Subjects between the ages of 17 and 75, who have sustained damage to primary visual cortex at age 17 or later, and are rendered blind over a portion of their visual field. * Subjects must have some intact visual cortical areas (other than primary visual cortex) in the damaged brain hemisphere. This assessment will be made from MRI or CT scans of the subject's head, which will be obtained via standard release from their neurologist. * Subjects who demonstrate a clear deficit in either simple or complex visual perception in portions of their visual field. * Subjects who are competent and responsible, as determined by the Principal Investigator. * Subjects who will receive retinal electrophysiology (mfERG) testing must have a report from their ophthalmologist stating that they are able to receive dilating drops Cortically Blind Subject Exclusion Criteria: * Subjects who do not possess damage of primary visual cortex or its immediate afferents * Subjects who are suffering from an active disease process involving their nervous system. * Subjects who are unable to fixate visual targets precisely with their eyes * Subjects who have unreliable vision fields from prior testing indicated by greater than 20% fixation losses, false positives or false negatives * Best corrected visual acuity worse than 20/40 in either eye * Impaired foveal sensitivity as indicated by visual field tests * Presence of vision loss from ocular disease or disorder * Presence of bilateral visual acuity loss from any source * Subjects who are suffering from one-sided attentional neglect * Subjects who have impaired auditory thresholds that would influence test results and training efficacy (all our testing and training involves sound as a cue for trial/stimulus onset or as feedback) * Persons who lack the competence or are otherwise unable to perform the visual training exercises as directed. Control Subject Inclusion Criteria: * Subjects must be between the ages of 17 and 75 years of age * Subjects must report no history of neurological disorder. * Subjects who are competent and responsible, as determined by the Principal Investigator. Control Subject Exclusion criteria: * Subjects who possess damage to the visual system * Subjects who are suffering from an active disease process involving their nervous system. * Subjects who are unable to fixate visual targets precisely with their eyes * Best corrected visual acuity worse than 20/40 in either eye * Presence of vision loss from ocular disease or disorder * Presence of bilateral visual acuity loss from any source * Subjects who are suffering from one-sided attentional neglect * Subjects who have impaired auditory thresholds that would influence test results and training efficacy (all our testing and training involves sound as a cue for trial/stimulus onset or as feedback) * Persons who lack the competence or are otherwise unable to perform the visual testing/training exercises as directed.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cortical blindness are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Flaum Eye Institute, University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase ⅱb/ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke
- AI may forecast stroke outcomes and guide recovery
- Robotic rehab may retrain the brain's sense of vertical after stroke
- Can immune cells heal the heart and brain after attack?
- Can a gentle ear zap supercharge stroke rehab at home?
- Magnetic pulses to the brain may help stroke survivors regain arm function